Cannabis / 08.05.2026

[caption id="attachment_73613" align="aligncenter" width="500"]therapeutic-uses-cannabis.jpg Pexels[/caption]

Please note: Cannabis and cannabidiol (CBD) products are generally not FDA tested or approved for all conditions referenced in this article. Cannabis and CBD products can interfere with medications including blood pressure medications and anticoagulants. Do not use cannabis products if pregnant, nursing or planning to become pregnant. Do not delay seeking medical attention for medical concerns by using cannabis or CBD products without medical advice. Cannabis products should not be used while driving or operating machinery. Statements and product contents have not been independently confirmed by MedicalResearch.com or Eminent Domains Inc. Please discuss any and all cannabis or CBD use with your health care provider before beginning any such regimen.

The landscape of chronic condition management has undergone a significant transformation over the past decade. For years, the medical community relied heavily on isolated symptom treatments and traditional pharmacological interventions to manage complex ailments. Patients suffering from long-term conditions like neuropathy, chronic inflammation, or severe anxiety frequently found themselves cycling through various medications with limited success and significant side effects. These recurring challenges have prompted healthcare professionals to rethink standard protocols. The latest clinical evidence supports a multidimensional approach to chronic pain that incorporates alternative and complementary therapies, reflecting a broader shift away from conventional, single-track treatments. As recent insights into pain management demonstrate, invasive procedures and heavy medications are no longer the default first-line defense. Instead, clinicians are increasingly advocating for whole-person care that values patient lifestyle strategies, psychological support, and alternative therapeutics. Among these emerging alternatives, cannabidiol has garnered substantial attention from the global medical and academic communities as a viable option for those who have exhausted standard therapies.
Author Interviews, Pain Research, Surgical Research / 28.04.2026

MedicalResearch.com Interview with a VERTEX Spokesperson discussing suzetrigine (JOURNAVX®), a first-in-class non-opioid pain signal inhibitor, and new Phase 4 data presented at the 2026 Annual Regional Anesthesiology and Acute Pain Medicine meeting.

MedicalResearch.com: What is the background for this study?

Response: There is a critical need for effective, safe non-opioid analgesics to help manage pain and reduce reliance on opioids. Despite significant safety and tolerability concerns such as addiction, opioid use disorder (OUD) and gastrointestinal side effects, opioids remain a common approach for managing moderate-to-severe acute pain. Our recent phase 4, single-arm study assessing suzetrigine in patients who underwent arthroscopic orthopedic procedures or laparoscopic abdominal or gynecological procedures highlighted the transformative potential for suzetrigine to be used as part of an opioid-free multimodal therapy for patients with moderate-to-severe acute pain. JOURNAVX® (suzetrigine) is a first-in-class, prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, including postoperative pain, in adults. It works by selectively inhibiting the NaV1.8 sodium channel on peripheral nociceptors and, therefore, is not believed to have the addiction potential and tolerability issues associated with centrally acting opioids.